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Colorectal cancer (CRC) accounts for about 4,000 deaths each year in Australia and is the second most 
common cause of cancer-related death after 
lung cancer.1 The 10-year risk of developing 
CRC for 60-year-old males is 1.2%; for females 
it is 0.8%. The good news is that the median 
five-year survival for those diagnosed with 
CRC has increased from 55.0% (1981-83) 
to 65.3% (2005-11) due to improved early 
diagnosis and advances in surgical and 
adjuvant therapy.2
Based on evidence from randomised 
controlled trials, screening with the faecal 
occult blood test (FOBT), followed by 
diagnostic colonoscopy for those testing 
positive, could prevent 14% of new CRC cases 
and 19% of deaths at an incremental cost of 
$58,540 per life-year saved compared with no 
screening.3,4 
In 2006, Australia began the National Bowel 
Cancer Screening Program (NBCSP) with the 
aim of reducing mortality rates associated 
with CRC.5 Once fully implemented, the 
NBCSP will offer free screening to those aged 
50 to 74 years, with biennial immunochemical 
faecal occult blood test (iFOBT). This is the 
most appropriate cohort for population 
screening because 93% of people diagnosed 
with CRC in Australia in 2011 were aged 50 
years or older.5
While the sensitivity of the NBCSP is high – 
83.4% of CRC identified within the program 
were first flagged by a positive iFOBT6 – its 
effectiveness is limited by a low uptake 
potentially due to cultural and linguistic 
diversity and psychological factors (faecal 
aversion). Although screening with FOBT 
in the United Kingdom (UK) has uptake of 
around 55%,7 just 36% of the Australian 
target population participated in the NBCSP 
in 2013-14.5
Colonoscopy is currently the gold standard 
for detection of CRC however, limited 
capacity (especially in the public system), 
high costs and test acceptability make it 
impractical for whole-population screening. 
Therefore, alternative approaches are 
required to improve screening participation 
and CRC detection, allowing more efficient 
and appropriate allocation of colonoscopy 
services. While the traditional public health 
CRC screening approach has stratified 
individuals for risk based primarily on age, 
other factors such as family history and 
lifestyle factors are known to affect individual 
risk. In addition, presence of adenomatous 
colonic polyp and adenoma characteristics 
(e.g. size, villosity, dysplasia grade and 
location in the colon) are predictive factors for 
future CRC.8 The NHMRC Clinical Guidelines 
for Colorectal Cancer detail how to stratify 
the population into risk categories based on 
family history.9 The guidelines recommend 
an increased level of surveillance via 
colonoscopy for those who have a strong 
family history of the disease or known genetic 
susceptibility. 
Family history, lifestyle and genetic 
prediction
Individuals vary in their levels of CRC risk 
based on differences in a complex array of 
factors including age, gender, family history, 
detected adenoma, genetic makeup and 
lifestyle or environmental factors including 
obesity and physical inactivity, diet and 
alcohol consumption. About 10-15% of the 
population have a family history of CRC, 
which increases an individual’s risk by 2–4 
fold.10 The increased risk associated with 
a family history of CRC in a first degree 
relative is equivalent to advancing the risk of 
developing CRC by about 10 years in both 
males and females.11 It seems logical that the 
age of entry into CRC screening programs 
should be adjusted based on family history. 
According to current evidence, the 
approximate two-fold risk associated with 
a family history of CRC has been attributed 
to genetic factors. Some of these are known 
mutations in specific genes that, when 
inherited, result in substantially increased risk 
of CRC.12 However, these genetic mutations 
are sufficiently rare (about 1 in 300 of the 
population) that they cannot account for the 
majority of the familial risk. This suggests that 
other genetic factors, if identifiable, could be 
used to predict CRC risk.12 
To date, the search for other genetic risk 
factors for CRC has primarily uncovered 
common, low-risk genetic variants, 
the majority being single-nucleotide 
polymorphisms (SNPs).13,14 So far, about 45 
SNPs have been identified that together 
contribute 23% of the heritable risk. A further 
5% can be attributed to the inheritance of 
high-penetrance mutations (Lynch, APC and 
MUTYH) in known genes.15 
It is clear that there remain as yet unidentified 
genetic factors contributing to a substantial 
proportion of the risk to developing CRC. To 
address this issue (and many other questions 
related to health and the genome), the United 
States (US) and the UK governments have 
independently announced large population-
based genome sequencing projects. The US 
Government has announced the Precision 
Medicine Cohort Program proposing to 
sequence the genomes of one million US 
participants, while the UK Government 
has commenced the 100,000 Genomes 
Project to sequence the genomes of 100,000 
people enrolled through the National 
Health Service. The investment in these two 
projects (US$215m and £300m respectively), 
is equivalent to A$935m. The expected 
outcomes are comprehensive knowledge of 
genetic risk profiles that can be used together 
with known lifestyle and environmental 
risk factors for better earlier diagnosis and 
personalised care for patients with cancer and 
other diseases. 
Risk stratification 
Much recent attention has focussed on 
strategies to improve the acceptability 
of iFOBT for CRC and other non-invasive 
screening tests, in addition to the 
development of risk stratification models 
for CRC screening. Risk stratification and 
personalised surveillance could substantially 
increase the detection rate and earlier 
detection for cancers in younger individuals 
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(especially for those under 50 years of age 
and therefore not eligible for the NBCSP), 
reduce the number of investigations for 
false-positive results, reduce the harm due to 
overuse of diagnostic or invasive treatments 
so that resources can be allocated to those 
who would benefit most from more regular 
surveillance.13 Furthermore, it has been 
suggested that personalised risk stratification 
could improve compliance with population 
CRC screening strategies.16 
The accumulated evidence suggests that a 
stratified risk screening strategy incorporating 
family history, age, gender, lifestyle, socio-
economic status with genetic profiling of 
multiple novel risk variants could improve 
CRC risk prediction. Although it cannot be 
applied to the prediction of individual risk 
for CRC at this time, it is possible to stratify a 
population into risk categories, using a panel 
of 10 common genetic variants associated 
with CRC susceptibility. Such a model is 
demonstrably superior to using family history 
alone.17 Risk stratification incorporating 
polygenic risk variants with family history, 
lifestyle and age can refine the risk prediction 
to identify 7% of the population at increased 
risk of developing CRC and for whom 
additional screening is warranted, through 
regular colonoscopic surveillance.17 A recent 
simulation study incorporating all the 45 
published SNPs for CRC estimated that 20% of 
the population could be identified that were 
1.8-times the average risk15. A person in this 
category reaches the average risk of a 63 year-
old by the time they are 56 years. If they also 
have a family history of CRC, they reach the 
risk of a 63 year-old at only 49 years.15
There is ample evidence to support genetic 
risk stratification for early identification of 
younger individuals at increased risk of CRC 
who are currently ineligible for population 
screening programs.18 Alternatively, the 
knowledge of increased CRC risk for age due 
to genetic predisposition, could promote 
participation in population CRC screening 
programs, such as the NBCSP.19 
Challenges
Despite the evidence and potential health 
gains, currently no population-level 
genetic risk stratification program exists 
anywhere in the world. We recognise that 
any proposal to incorporate such measures 
will introduce a range of new challenges for 
current population screening policy makers. 
Before implementing a risk stratification 
model for CRC screening, there are many 
fundamental economic, ethical and policy 
issues to be resolved, including the secure 
sample storage, privacy and confidentiality of 
identifiable personal data and linking these to 
other phenotypic data, and consent to access 
to genetic, lifestyle and medical records over 
a person’s lifetime.20 These may or may not 
support genetic risk stratification, but must 
be investigated thoroughly to ensure that 
any decisions concerning whether or not 
to introduce a new risk-based paradigm are 
based on sound evidence and community 
acceptability. If it were to be introduced, a 
communication strategy will be required to 
educate the public about how to use genetic 
information to balance the risks and benefits 
of risk stratification. Individual consent will 
be required that includes provision for re-
contact to communicate new information 
or incidental findings, limitations on the 
scope of genetic testing, linkages to other 
databases and implications for employment 
and insurance. It is time that these matters 
are brought to the attention of the funders 
of research, policy makers and the general 
public so that they can be considered and 
planned to meet societal standards. 
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